Literature DB >> 7511684

T cell responses and virus evolution: loss of HLA A11-restricted CTL epitopes in Epstein-Barr virus isolates from highly A11-positive populations by selective mutation of anchor residues.

P O de Campos-Lima1, V Levitsky, J Brooks, S P Lee, L F Hu, A B Rickinson, M G Masucci.   

Abstract

Epstein-Barr virus (EBV) is a B lymphotropic herpesvirus of humans that elicits strong HLA class I-restricted cytotoxic T lymphocyte (CTL) responses. An influence of such responses on virus evolution was first suggested by our finding that EBV isolates from the highly HLA A11-positive Papua New Guinea (PNG) population carried a lys-thr mutation at residue 424 of the nuclear antigen EBV-encoded nuclear antigen (EBNA4) that destroyed the immunodominant target epitope for A11-restricted CTL recognition. Here we turn to a much larger population, Southern Chinese, where the A11 allele is again present in over 50% of the individuals. Each of 23 EBV isolates analyzed from this population were also mutated in the EBNA4 416-424 epitope, the mutations selectively involving one of the two anchor residues in positions 2 (417 val-leu) or 9 (424 lys-asp, -arg or -thr) that are critical for A11-peptide interaction. The majority of the Chinese isolates and all 10 PNG isolates also carried mutations affecting positions 1 and 2 of the next most immunodominant A11-restricted epitope, EBNA4 residues 399-408. These changes clearly affected antigenicity since A11-positive lymphoblastoid cell lines (LCLs) carrying these mutant EBV strains were not recognized by A11-restricted CTLs raised against the prototype B95.8 virus. Furthermore, Chinese donors naturally infected with these mutant viruses did not mount detectable A11-restricted CTL responses on in vitro stimulation with autologous LCL cells carrying either the B95.8 or their endogenous EBV strain. In two different highly A11-positive populations, therefore, immune pressure appears to have selected for resident EBV strains lacking immunodominant A11-restricted CTL epitopes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7511684      PMCID: PMC2191457          DOI: 10.1084/jem.179.4.1297

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  25 in total

1.  Standards for total serum protein assays--a collaborative study.

Authors:  B T Doumas
Journal:  Clin Chem       Date:  1975-07       Impact factor: 8.327

2.  Recognition of the Epstein-Barr virus-encoded nuclear antigens EBNA-4 and EBNA-6 by HLA-A11-restricted cytotoxic T lymphocytes: implications for down-regulation of HLA-A11 in Burkitt lymphoma.

Authors:  R Gavioli; P O De Campos-Lima; M G Kurilla; E Kieff; G Klein; M G Masucci
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-01       Impact factor: 11.205

3.  Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus.

Authors:  K L Yap; G L Ada; I F McKenzie
Journal:  Nature       Date:  1978-05-18       Impact factor: 49.962

4.  An HLA-A11-specific motif in nonamer peptides derived from viral and cellular proteins.

Authors:  Q J Zhang; R Gavioli; G Klein; M G Masucci
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

5.  An HLA map of Europe.

Authors:  L P Ryder; E Andersen; A Svejgaard
Journal:  Hum Hered       Date:  1978       Impact factor: 0.444

6.  Release of infectious Epstein-Barr virus by transformed marmoset leukocytes.

Authors:  G Miller; M Lipman
Journal:  Proc Natl Acad Sci U S A       Date:  1973-01       Impact factor: 11.205

7.  Spontaneous release of a factor with properties of T cell growth factor from a continuous line of primate tumor T cells.

Authors:  H Rabin; R F Hopkins; F W Ruscetti; R H Neubauer; R L Brown; T G Kawakami
Journal:  J Immunol       Date:  1981-11       Impact factor: 5.422

8.  HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2.

Authors:  S P Lee; W A Thomas; R J Murray; F Khanim; S Kaur; L S Young; M Rowe; M Kurilla; A B Rickinson
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

9.  Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development.

Authors:  R Khanna; S R Burrows; M G Kurilla; C A Jacob; I S Misko; T B Sculley; E Kieff; D J Moss
Journal:  J Exp Med       Date:  1992-07-01       Impact factor: 14.307

10.  Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide.

Authors:  J M Brooks; R J Murray; W A Thomas; M G Kurilla; A B Rickinson
Journal:  J Exp Med       Date:  1993-09-01       Impact factor: 14.307

View more
  56 in total

1.  EBNA-1 sequences in endemic and sporadic Burkitt's lymphoma.

Authors:  K Bhatia; I Magrath
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

2.  The lifespan of major histocompatibility complex class I/peptide complexes determines the efficiency of cytotoxic T-lymphocyte responses.

Authors:  F Micheletti; M Bazzaro; A Canella; M Marastoni; S Traniello; R Gavioli
Journal:  Immunology       Date:  1999-03       Impact factor: 7.397

3.  Antigenic drift in the influenza A virus (H3N2) nucleoprotein and escape from recognition by cytotoxic T lymphocytes.

Authors:  J T Voeten; T M Bestebroer; N J Nieuwkoop; R A Fouchier; A D Osterhaus; G F Rimmelzwaan
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

4.  Latent gene sequencing reveals familial relationships among Chinese Epstein-Barr virus strains and evidence for positive selection of A11 epitope changes.

Authors:  R S Midgley; A I Bell; D J McGeoch; A B Rickinson
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

5.  Major histocompatibility complex controls the trajectory but not host-specific adaptation during virulence evolution of the pathogenic fungus Cryptococcus neoformans.

Authors:  Erin E McClelland; Frederick R Adler; Donald L Granger; Wayne K Potts
Journal:  Proc Biol Sci       Date:  2004-08-07       Impact factor: 5.349

6.  Specific mutation of a gammaherpesvirus-expressed antigen in response to CD8 T cell selection in vivo.

Authors:  Joy Loh; Daniel L Popkin; Lindsay Droit; Douglas C Braaten; Guoyan Zhao; Xin Zhang; Punit Vachharajani; Nancy Myers; Ted H Hansen; Herbert W Virgin
Journal:  J Virol       Date:  2011-12-14       Impact factor: 5.103

7.  Epstein-Barr virus isolates retain their capacity to evade T cell immunity through BNLF2a despite extensive sequence variation.

Authors:  Daniëlle Horst; Scott R Burrows; Derek Gatherer; Bonnie van Wilgenburg; Melissa J Bell; Ingrid G J Boer; Maaike E Ressing; Emmanuel J H J Wiertz
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

8.  Relation between viral fitness and immune escape within the hepatitis C virus protease.

Authors:  J Söderholm; G Ahlén; A Kaul; L Frelin; M Alheim; C Barnfield; P Liljeström; O Weiland; D R Milich; R Bartenschlager; M Sällberg
Journal:  Gut       Date:  2005-08-16       Impact factor: 23.059

9.  HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release.

Authors:  M J Koziel; D Dudley; N Afdhal; A Grakoui; C M Rice; Q L Choo; M Houghton; B D Walker
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

10.  Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant.

Authors:  A Weiner; A L Erickson; J Kansopon; K Crawford; E Muchmore; A L Hughes; M Houghton; C M Walker
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.